Globalising the access to advanced molecular diagnostics of CNS tumors: Experience of the Molecular Neuro-Pathology (MNP) Outreach Consortium

Clicks: 2
ID: 332114
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #265 of 265 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 265 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Central nervous system (CNS) tumors pose a major global health challenge, particularly in low- and middle-income countries (LMICs), where outcomes remain disproportionately poor. The global CONCORD-3 study (Lancet Oncology) highlighted stark disparities in five-year survival (2010-2014): from ∼15% in Thailand to 46% in Japan among adults, and from ∼ 80% in Denmark to < 40% in Brazil among children. Limited access to specialized pathology and molecular diagnostics in LMICs results in diagnostic uncertainty and restricted treatment options. DNA methylation-based tumor classification, has revolutionized CNS tumor diagnosis and got incorporated into the 2021 world health organization (WHO) CNS5 classification. However, its accessibility, feasibility, and performance in LMICs remain insufficiently explored. Importantly, several ethnic groups common in LMICs are underrepresented in current reference datasets. To address this, the Molecular Neuro-Pathology (MNP) Outreach Consortium was launched in Heidelberg, partnering with 11 countries-including nine LMICs from Asia, Africa, and South America. Early insights from Brazil, Jordan and Argentina, show methylation profiling changing diagnosis in up to 25% cases. Gains are greatest in pediatric and adolescents and young adults (AYA) populations. In addition, it reduced the designation of not otherwise specified (NOS) from 51.3% to 8.8% across 476 CNS tumours in Brazil.
Reference Key
openalex_W7221512556 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Olfat Ahmad, Felipe D’Almeida Costa, Wouter Hendrickx, Ahmed Gilani, Vaishali S. Suri, Nabe Al-Hasnawi, Monique Stenzel, Martin Lablans, Syed Ather Enam, Shahenda El‐Naggar, Horacio Martinetto, Gustavo Sevlever, Blanca Diez, Maysa A. Al-Hussaini, Sith Sathornsumetee, Thidathip Wongsurawat, Ludi Dhyani Rahmartani, Naureen Mushtaq, Erdener Özer, Christophe Michel Raynaud, Paromita Roy, Sushant Vinarkar, Rimpa Basu Achari, Pablo Zoroquiain, Roger Gejman, Cristovam Scapulatempo Neto, Leslie Domenici Kulikowski, João Victor Alves de Castro, Luiz Gustavo Dufner‐Almeida, Beatriz Martins Wolff, Yuri Reis Casal, Khurram Minhas, Andréa Maria Cappellano, Stefan Hamelmann, Mohamed Shebl Abdelbaki, Lorena Baroni, Abrar Al-Masamreh, Abdlrahman Eswed, Ute Katharina Bartels, Dominik Sturm, Martin Sill, David T. W. Jones, Areeba Patel, Felix Sahm, Stefan M. Pfister
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag077
URL
https://doi.org/10.1093/neuonc/noag077
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.